DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis

Genitourinary Cancer

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer

Prostate Cancer Prostatic Dis

Morgans AK, Wallis CJD, Halabi S, Armstrong AJ, Adorjan P, Ghadessi M, Verholen F, Grimm MO

doi: 10.1038/s41391-026-01076-w

Genitourinary Cancer

Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial

Lancet Oncol

Fizazi K, Morris MJ, Shore ND, Chi KN, Crosby M, de Bono JS, Herrmann K, Roubaud G, Nagarajah J, Fleming M, Lewis B, Nordquist L, Carnahan N, Ghebremariam S, Hertelendi M, Castellano D, Sartor O

doi: 10.1016/S1470-2045(25)00189-5

Genitourinary Cancer

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

Int J Cancer

Incorvaia L, Santini D, Matrana MR, Maruzzo M, Kopp RM, Antonuzzo L, Bracarda S, Tural D, Procopio G, Bourlon MT, Caffo O, Zapata Laguado MI, Di Maio M, Maiorano BA, Conteduca V, Rossetti S, Lipari H, Büttner T, Rizzo M, Ürün Y, Messina C, Marques Monteiro FS, Soares A, Puglisi M, Principi A, Lai E, Mammone G, Stellato M, Depetris I, Bazan Russo TD, Spricido IY, Gismondi CBL, Massari F, Pavan N, Santoni M, Taha T

doi: 10.1002/ijc.70679

Genitourinary Cancer

Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer

Clin Cancer Res

Jani CT, Tran E, Zhang N, Tsai J, Dong J, Bucheit L, Pan E, Panian J, Chen YW, McKay RR

doi: 10.1158/1078-0432.CCR-25-3071

Genitourinary Cancer

Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries

Eur Urol

Light A, Peters M, Gopalakrishnan A, Mayor N, Cullen E, Boaz RJ, Norris JM, Morris S, Arya M, Tanaka MB, Doherty A, Dudderidge T, Emara A, Emberton M, Grey A, Hindley R, Laniado M, McCraken S, Moore CM, Nigam R, Noureldin M, Orczyk C, Rakauskas A, Simmons L, Virdi J, Withington J, Zakikhani P, Ahmed HU, Shah TT

doi: 10.1016/j.eururo.2026.05.007

Genitourinary Cancer

Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis

Prostate

Garcia de Herreros M, Rodrigo C, Ferrer-Mileo L, Fernández-Mañas L, Mases J, Diaz N, Vilaseca A, Altamirano M, Gibanel R, Ribal MJ, Jimenez N, Reig O, Figols M, Climent MÁ, Font A, Mellado B

doi: 10.1002/pros.70174

Gastrointestinal Cancer

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Int J Cancer

Goetze TO, Al-Batran SE, Liersch R, Scheuer L, Goehler T, Kaiser U, Denzlinger C, Brandl S, Pink D, Uhlig J, Maasberg M, Loose M, Schaaf M, Sookthai D, Zäpf B, Pauligk C, Habibzade T, Hofheinz RD, Koch C, AIO Study Group

doi: 10.1002/ijc.70280

Genitourinary Cancer

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1

J Clin Oncol

Taplin ME, Riaz IB, Rumble RB, Naqvi SAA, Hope TA, Dias MF, He H, Hotte SJ, Emamekhoo H, Murad MH, Celano P, Kungel TM, Hentzen S, Serzan MT, Parikh RA

doi: 10.1200/JCO-25-02693

Genitourinary Cancer

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis

Prostate Cancer Prostatic Dis

Saporita I, Calabrese M, Carfi FM, Mogavero A, Puglisi M, Treglia G, Vogl UM, Gillessen S, Pereira Mestre R, Pedrani M, Pecoraro G, Salfi G, Erhart CC, Lin HM, Tortola L, Di Maio M, Tucci M, Buttigliero C, Turco F

doi: 10.1038/s41391-026-01077-9

Related content

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer

Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer

Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries

Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis